About this event
Late-stage formulation decisions can directly impact commercialization readiness, timelines, regulatory alignment and long-term product strategy.
In this webinar, we discuss how teams generate decision-ready data to reduce uncertainty and make formulation decisions they can defend.
The session includes real-world perspectives from a late-stage biologics program at Akero, now part of Novo Nordisk.
→ Move beyond more data and focus on the data that actually supports decisions.
→ Understand how structured, iterative development helps teams navigate formulation complexity.
→ Build confidence for internal alignment, regulatory discussions and commercialization readiness.
In drug product development, critical decisions must be made under uncertainty—often with limited time, data, and clarity.
Leukocare enables teams to make the right decisions faster by turning complex formulation challenges into a structured, science-driven and decision-focused process.
